GO:0150153 positive regulation of interleukin-17A production: Immune Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0150153 describes any process that activates or increases the frequency, rate or extent of interleukin-17A (IL-17A) production.
• IL-17A is a signature cytokine of T helper 17 (Th17) cells, but is also produced by gamma-delta T cells, innate lymphoid cells (ILC3s), and other innate-like lymphocytes.
• Positive regulation of IL-17A production is controlled by a network of transcription factors, cytokines, and co-stimulatory signals, including STAT3, RORγt, and IL-23.
• Dysregulated IL-17A production contributes to autoimmune diseases such as psoriasis, colitis, and pulmonary fibrosis, and also shapes tumor immunity.
• CRISPR-based models (knockout, knock-in, overexpression) are powerful tools to dissect the genetic and signaling requirements for IL-17A production.
• Targeting IL-17A or its upstream regulators is a validated therapeutic strategy in autoimmunity and is being explored in cancer immunotherapy.
Description
Interleukin-17A (IL-17A) is a pleiotropic cytokine that plays a central role in host defense and inflammatory pathology. The Gene Ontology term GO:0150153, positive regulation of interleukin-17A production, captures the biological processes that increase the synthesis and secretion of IL-17A. This term is essential for annotating gene function in immunology, as it integrates signals from pattern recognition receptors, cytokines, and transcription factors that converge on IL-17A expression. Understanding this process is critical for researchers studying autoimmune diseases, cancer, and host-microbe interactions. The term is defined as any process that activates or increases the frequency, rate or extent of interleukin-17A production. It encompasses transcriptional, post-transcriptional, and signaling events that lead to elevated IL-17A levels. Because IL-17A is a key effector cytokine in Th17-mediated immunity, its positive regulation is a focal point for therapeutic intervention. This article provides a comprehensive overview of the mechanisms, genes, and research methods associated with GO:0150153, based on authoritative QuickGO data and published literature.
positive regulation of interleukin-17A production At A Glance
| GO ID | GO:0150153 |
|---|---|
| GO term | positive regulation of interleukin-17A production |
| Ontology | biological_process |
| Synonym | positive regulation of interleukin-17A biosynthetic process |
| Major function | Upregulation of IL-17A cytokine production in immune cells |
| Related cytokines | IL-17A, IL-23, IL-1β, IL-6, TGF-β |
| Key transcription factors | RORγt, STAT3, BATF, IRF4 |
| Cell types involved | Th17 cells, γδ T cells, ILC3s, NKT cells |
What Is GO:0150153?
GO:0150153, positive regulation of interleukin-17A production, is a biological process term defined as any process that activates or increases the frequency, rate or extent of interleukin-17A production. It includes signaling pathways, transcription factor activity, and cellular interactions that enhance the expression and secretion of IL-17A. This term is a child of regulation of interleukin-17A production and is distinct from negative regulation or generic regulation.
Why Is positive regulation of interleukin-17A production Important in Cell Biology?
Positive regulation of IL-17A production is a central node in inflammatory and autoimmune diseases, and its manipulation holds therapeutic promise. IL-17A is the hallmark cytokine of Th17 cells, which are implicated in psoriasis, inflammatory bowel disease, multiple sclerosis, and rheumatoid arthritis. In cancer, IL-17A can promote tumorigenesis or enhance anti-tumor immunity depending on context. Therefore, understanding how IL-17A production is positively regulated is essential for developing targeted therapies.
• IL-17A is a key driver of autoimmune and inflammatory diseases such as psoriasis and colitis.
• Positive regulation of IL-17A production is critical for host defense against extracellular bacteria and fungi.
• IL-17A can promote tumor progression in colorectal cancer, and blocking it enhances anti-PD-1 immunotherapy.
• In pulmonary fibrosis, PD-1 upregulation on CD4+ T cells promotes IL-17A production via STAT3.
• IL-17A-mediated mitochondrial dysfunction induces pyroptosis in colorectal cancer cells.
• NRP1 instructs IL-17-producing ILC3s to drive colitis progression.
• Sympathetic nerves secreting norepinephrine regulate IL-17A production in psoriasis.
• IL-17A production is regulated by a complex network of cytokines including IL-23, IL-1β, and IL-6.
• Genetic variants in IL17A and its regulators are associated with susceptibility to autoimmune diseases.
• CRISPR screening can identify novel regulators of IL-17A production for therapeutic targeting.
What Happens During positive regulation of interleukin-17A production?
Initiation by Cytokine Signals
In simple terms: Cytokines like IL-23 and IL-1β tell immune cells to start making IL-17A.
Positive regulation of IL-17A production begins when antigen-presenting cells secrete cytokines such as IL-23, IL-1β, and IL-6 in response to pathogens or inflammatory stimuli. These cytokines bind to their receptors on naive CD4+ T cells, γδ T cells, or ILC3s, triggering intracellular signaling cascades. For example, IL-23 stabilizes the Th17 phenotype and promotes IL-17A transcription. In ILC3s, NRP1 acts as a receptor that instructs these cells to produce IL-17A and drive colitis.
Transcriptional Activation of IL17A
In simple terms: Transcription factors like RORγt and STAT3 turn on the IL17A gene.
Upon cytokine stimulation, transcription factors including RORγt, STAT3, BATF, and IRF4 are activated and bind to regulatory elements of the IL17A locus. STAT3 is phosphorylated by JAK kinases downstream of IL-23 and IL-6 receptors, and it promotes IL-17A expression. In pulmonary fibrosis, PD-1 upregulation on CD4+ T cells enhances STAT3-mediated IL-17A production. RORγt is the master transcription factor for Th17 cells and is required for IL17A gene expression.
Epigenetic and Post-transcriptional Control
In simple terms: Chemical marks on DNA and RNA stability affect how much IL-17A is made.
Epigenetic modifications, including histone acetylation and DNA methylation, regulate accessibility of the IL17A promoter and enhancer regions. Post-transcriptional mechanisms such as mRNA stability and microRNA-mediated regulation also modulate IL-17A production. For instance, certain microRNAs can target the 3' untranslated region of IL17A mRNA to suppress its translation. These layers of control ensure that IL-17A production is tightly regulated and can be rapidly increased upon appropriate stimulation.
Cellular Metabolism and IL-17A Production
In simple terms: How cells use energy influences their ability to produce IL-17A.
Metabolic reprogramming, including glycolysis and mitochondrial function, supports the differentiation and effector function of IL-17-producing cells. In colorectal cancer cells, IL-17A-mediated mitochondrial dysfunction induces pyroptosis, a form of inflammatory cell death. This suggests that mitochondrial activity is not only a consequence but also a regulator of IL-17A production and its downstream effects. Targeting metabolic pathways may therefore modulate IL-17A production in disease contexts.
Neuro-immune Regulation
In simple terms: Nerves can release chemicals that boost IL-17A production.
The nervous system can positively regulate IL-17A production. In psoriasis, cutaneous calcium/calmodulin-dependent protein kinase II-γ-positive sympathetic nerves secrete norepinephrine, which dictates IL-17A production and disease severity. This neuro-immune crosstalk highlights that IL-17A production is influenced by neural signals in addition to classical immune stimuli. Understanding these interactions may open new avenues for treating inflammatory skin diseases.
Key Genes Involved in GO:0150153 positive regulation of interleukin-17A production
The following genes and proteins are key players in the positive regulation of IL-17A production, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL17A | Encodes the IL-17A cytokine itself | Direct target of regulation; mutations affect cytokine levels |
| RORC | Encodes RORγt, master transcription factor for Th17 cells | Essential for IL17A transcription; knockout abolishes Th17 development |
| STAT3 | Signal transducer and activator of transcription 3 | Mediates IL-23 and IL-6 signaling to promote IL-17A production |
| IL23A | Subunit of IL-23 cytokine | Stabilizes Th17 cells and promotes IL-17A production |
| IL1B | Pro-inflammatory cytokine IL-1β | Synergizes with IL-23 to induce IL-17A |
| IL6 | Cytokine IL-6 | Together with TGF-β, drives Th17 differentiation and IL-17A production |
| NRP1 | Neuropilin-1 receptor | Instructs ILC3s to produce IL-17A and drive colitis |
| PDCD1 | Programmed cell death protein 1 (PD-1) | Upregulation on CD4+ T cells promotes STAT3-mediated IL-17A production in fibrosis |
| BATF | Basic leucine zipper transcription factor | Cooperates with RORγt to activate IL17A transcription |
| IRF4 | Interferon regulatory factor 4 | Required for Th17 differentiation and IL-17A production |
| AHR | Aryl hydrocarbon receptor | Promotes Th17 differentiation and IL-17A expression |
| TGFB1 | Transforming growth factor beta 1 | Induces Th17 differentiation and IL-17A production |
| IL17F | IL-17F cytokine | Co-expressed with IL-17A; shares regulatory mechanisms |
| CCR6 | Chemokine receptor | Marks Th17 cells and influences IL-17A production |
| RORA | RAR-related orphan receptor alpha | Contributes to Th17 differentiation and IL-17A expression |
| STAT5 | Signal transducer and activator of transcription 5 | Can modulate IL-17A production in certain contexts |
| FOXP3 | Forkhead box P3 | Regulatory T cell transcription factor; antagonizes Th17 and IL-17A production |
| IL2 | Interleukin-2 | Inhibits Th17 differentiation and IL-17A production |
How Is positive regulation of interleukin-17A production Regulated?
The positive regulation of IL-17A production is tightly controlled by a balance of stimulatory and inhibitory signals. Key positive regulators include IL-23, IL-1β, IL-6, and TGF-β, which activate STAT3 and RORγt. Negative regulators include IL-2, which promotes regulatory T cell differentiation and suppresses Th17 cells. Additionally, PD-1 upregulation on CD4+ T cells can enhance STAT3-mediated IL-17A production in the context of pulmonary fibrosis. Neuro-immune signals, such as norepinephrine from sympathetic nerves, can also positively regulate IL-17A production in psoriasis. This complex regulation ensures that IL-17A production is appropriate to the context and is a target for therapeutic intervention.
positive regulation of interleukin-17A production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL17A | Psoriasis, colitis, colorectal cancer | IL17A knockout mice; overexpression in T cells |
| STAT3 | Pulmonary fibrosis, autoimmunity | STAT3 conditional knockout in CD4+ T cells |
| NRP1 | Colitis progression | NRP1 knockout in ILC3s; colitis mouse models |
| PDCD1 | Pulmonary fibrosis | PD-1 knockout or overexpression in CD4+ T cells |
| RORC | Autoimmune diseases | RORγt knockout mice; Th17 differentiation assays |
IL-17A in Autoimmune and Inflammatory Diseases
Dysregulated positive regulation of IL-17A production is a hallmark of several autoimmune diseases. In psoriasis, IL-17A drives keratinocyte hyperproliferation and inflammation, and sympathetic nerve-derived norepinephrine enhances IL-17A production. In inflammatory bowel disease, IL-17-producing ILC3s instructed by NRP1 promote colitis progression. Pulmonary fibrosis is exacerbated by PD-1-mediated upregulation of STAT3, which increases IL-17A and TGF-β1 production. These examples highlight the pathological consequences of excessive IL-17A production.
IL-17A in Cancer
The role of IL-17A in cancer is context-dependent. In microsatellite stable colorectal cancer, blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy, suggesting that IL-17A promotes immune evasion. Conversely, IL-17A-mediated mitochondrial dysfunction can induce pyroptosis in colorectal cancer cells and promote CD8+ T-cell infiltration, indicating an anti-tumor role in some settings. Thus, positive regulation of IL-17A production can have opposing effects on tumor progression, and therapeutic targeting must consider the specific tumor microenvironment.
IL-17A in Host Defense
IL-17A is critical for protective immunity against extracellular bacteria and fungi, particularly at mucosal surfaces. Positive regulation of IL-17A production is essential for recruiting neutrophils and inducing antimicrobial peptides. However, excessive or chronic IL-17A production can lead to tissue damage and autoimmunity. Understanding the balance between protective and pathogenic IL-17A responses is a major research focus.
From positive regulation of interleukin-17A production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate IL-17A production? | CRISPR knockout of gene X in primary T cells or cell lines |
| Does a specific mutation in gene X affect IL-17A production? | CRISPR point mutation knock-in in cell lines |
| Does overexpression of gene X increase IL-17A? | CRISPR knock-in of a constitutive promoter or cDNA overexpression |
| Where is gene X expressed in IL-17-producing cells? | Tagged knock-in with fluorescent reporter |
| What is the effect of gene X on colitis? | Adoptive transfer of CRISPR-edited T cells into mouse colitis models |
| Can we identify novel regulators of IL-17A? | Genome-wide CRISPR library screening in Th17 cells |
How to Study the positive regulation of interleukin-17A production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Loss-of-function effects on IL-17A production | Identify novel regulators |
| Intracellular cytokine staining | Percentage of IL-17A+ cells | Validate CRISPR phenotypes |
| ELISA | Secreted IL-17A concentration | Quantify cytokine production |
| RNA-seq | Transcriptional changes | Define gene expression programs |
| ATAC-seq | Chromatin accessibility | Identify regulatory elements at IL17A locus |
| Adoptive transfer colitis model | Disease severity and IL-17A production | Test gene function in vivo |
| Single-cell RNA-seq | Heterogeneity of IL-17-producing cells | Dissect cell subsets |
CRISPR Screening for Regulators of IL-17A Production
Genome-wide CRISPR knockout or activation screens can identify genes that positively or negatively regulate IL-17A production. In these screens, cells are edited with a library of guide RNAs, stimulated to produce IL-17A, and then sorted based on cytokine expression. Next-generation sequencing reveals enriched or depleted guides, pinpointing candidate regulators. This approach has been used to discover novel pathways controlling IL-17A in cancer and autoimmunity.
Flow Cytometry and Cytokine Assays
Flow cytometry is the gold standard for measuring IL-17A production at the single-cell level. Intracellular cytokine staining after brief stimulation with PMA/ionomycin and brefeldin A allows identification of IL-17A+ cells among T cells, ILC3s, and other populations. ELISA and multiplex assays quantify secreted IL-17A in culture supernatants or serum. These methods are essential for validating CRISPR-edited phenotypes.
Transcriptomic and Epigenomic Profiling
RNA-seq and ATAC-seq can reveal transcriptional and chromatin changes associated with positive regulation of IL-17A production. By comparing wild-type and CRISPR-edited cells, researchers can identify gene expression programs and regulatory elements that drive IL17A transcription. Single-cell RNA-seq further resolves heterogeneity among IL-17-producing cell subsets.
In Vivo Models of IL-17A-Mediated Disease
Mouse models of colitis, psoriasis, and pulmonary fibrosis are used to study the role of positive regulation of IL-17A production in disease. Adoptive transfer of CRISPR-edited T cells or conditional knockout mice allows causal testing of candidate genes. These models are critical for translating in vitro findings to human pathology.
How CRISPR Can Be Used to Study GO:0150153 positive regulation of interleukin-17A production
Knockout
CRISPR knockout is used to delete candidate genes and assess their requirement for IL-17A production. For example, knocking out NRP1 in ILC3s reduces IL-17A production and ameliorates colitis in mouse models. Similarly, STAT3 knockout in CD4+ T cells abolishes IL-17A production in pulmonary fibrosis models. Knockout screens can systematically identify positive regulators of IL-17A.
Point Mutation
CRISPR point mutation knock-in allows precise introduction of disease-associated or functional variants into the genome. This is useful for studying how specific amino acid changes in transcription factors like STAT3 or RORγt affect IL-17A production. Point mutations can also be used to disrupt phosphorylation sites or DNA-binding domains to dissect signaling pathways.
Knock-in
Knock-in of reporter genes (e.g., GFP) or epitope tags into the IL17A locus enables tracking of IL-17A-producing cells in real time. Knock-in of constitutive or inducible promoters can drive overexpression of candidate regulators to test sufficiency. These models are valuable for isolating live IL-17A+ cells for downstream analysis.
Overexpression
CRISPR-mediated overexpression, such as by knocking in a strong promoter or using CRISPR activation (CRISPRa), can test whether a gene is sufficient to drive IL-17A production. Overexpression of NRP1 in ILC3s, for instance, might enhance IL-17A production and exacerbate colitis. Overexpression models complement knockout studies to establish causality.
How EDITGENE Supports positive regulation of interleukin-17A production Research
Researchers studying positive regulation of interleukin-17A production-related genes often need to determine whether a candidate gene is causally involved in driving IL-17A expression, and to dissect the underlying molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of interleukin-17A production research.
Frequently Asked Questions About positive regulation of interleukin-17A production
What is GO:0150153?
GO:0150153 is the Gene Ontology term for positive regulation of interleukin-17A production, defined as any process that activates or increases the frequency, rate or extent of IL-17A production.
What genes are involved in positive regulation of IL-17A production?
Key genes include IL17A, RORC, STAT3, IL23A, IL1B, IL6, NRP1, PDCD1, BATF, and IRF4, among others.
How is IL-17A production regulated?
IL-17A production is regulated by cytokines such as IL-23, IL-1β, and IL-6, which activate transcription factors like STAT3 and RORγt, as well as by neuro-immune signals and metabolic pathways.
What diseases are associated with increased IL-17A production?
Increased IL-17A production is associated with psoriasis, inflammatory bowel disease, pulmonary fibrosis, and certain cancers.
What cell types produce IL-17A?
IL-17A is primarily produced by Th17 cells, but also by γδ T cells, ILC3s, NKT cells, and other innate-like lymphocytes.
How can CRISPR be used to study IL-17A regulation?
CRISPR knockout, knock-in, point mutation, and overexpression models allow researchers to test the causal role of specific genes in IL-17A production.
What is the role of STAT3 in IL-17A production?
STAT3 is a key transcription factor downstream of IL-23 and IL-6 that promotes IL-17A production, and its upregulation is linked to pulmonary fibrosis.
What is the role of NRP1 in IL-17A production?
NRP1 instructs ILC3s to produce IL-17A and drive colitis progression, as shown in knockout and adoptive transfer studies.
Can IL-17A be targeted therapeutically?
Yes, blocking IL-17A is a validated strategy for autoimmune diseases, and in colorectal cancer it enhances response to anti-PD-1 immunotherapy.
What methods are used to measure IL-17A production?
Common methods include intracellular cytokine staining, ELISA, RNA-seq, and CRISPR screening.
Conclusion
GO:0150153, positive regulation of interleukin-17A production, is a critical biological process that governs the expression of a key inflammatory cytokine. Its dysregulation underlies numerous autoimmune and inflammatory diseases, and it plays complex roles in cancer. Understanding the genetic and signaling networks that positively regulate IL-17A production is essential for developing targeted therapies. CRISPR-based models and screening approaches offer powerful tools to dissect these mechanisms and identify new therapeutic targets.
References
- 1. Mills KHG. 2023. IL-17 and IL-17-producing cells in protection versus pathology.. Nat Rev Immunol 23(1):38-54 PMID: 35790881
- 2. Liu C et al.. 2021. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.. J Immunother Cancer 9(1) PMID: 33462141
- 3. Celada LJ et al.. 2018. PD-1 up-regulation on CD4(+) T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production.. Sci Transl Med 10(460) PMID: 30257954
- 4. Wang Y et al.. 2025. NRP1 instructs IL-17-producing ILC3s to drive colitis progression.. Cell Mol Immunol 22(2):161-175 PMID: 39741194
- 5. Chen K et al.. 2017. Interluekin-17A (IL17A).. Gene 614:8-14 PMID: 28122268
- 6. Feng WQ et al.. 2023. IL-17A-mediated mitochondrial dysfunction induces pyroptosis in colorectal cancer cells and promotes CD8 + T-cell tumour infiltration.. J Transl Med 21(1):335 PMID: 37211606
- 7. Chen Z et al.. 2008. Regulation of IL-17 production in human lymphocytes.. Cytokine 41(2):71-8 PMID: 17981475
- 8. Yu Y et al.. 2024. Cutaneous Calcium/Calmodulin-Dependent Protein Kinase II-γ-Positive Sympathetic Nerves Secreting Norepinephrine Dictate Psoriasis.. Adv Sci (Weinh) 11(23):e2306772 PMID: 38544478
